Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SCOLR drops PE plans

This article was originally published in The Tan Sheet

Executive Summary

SCOLR Pharma announces Feb. 6 it will no longer continue the development of a 12-hour CDT-based phenylephrine formulation. The Bellevue, Wash.-based firm says the recently completed non-optimized CDT-based extended release PE trial "provided valuable data but does not justify continued internal development." SCOLR Pharma's VP and Chief Technology Officer Stephen Turner says the firm plans to focus its resources on an extended release formulation of pseudoephedrine with the goal of filing an ANDA later this year...
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS100237

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel